A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery

Ding, Tian-Yan; Liu, Can-Tong; Huang, Bin-Liang; Chu, Ling-Yu; Wei, Lai‐Feng; Lin, Yiwei; Luo, Yun; Zhang, Biao; Hong, Chao‐Qun; Xu, Yi‐Wei; Peng, Yu‐Hui

doi:10.2147/cmar.s329687

Cited by 11 publications

(10 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nomograms based on traditional demographic characteristics (such as age, sex, and race) and clinicopathological features (such as TNM stage, tumor location, tumor size, tumor grade, depth of invasion, and number of metastases) only show a moderate performance ( 16 , 19 , 20 ). Some studies have incorporated the nutritional information and inflammatory profile of patients into the nomogram and successfully demonstrated that the developed nomogram has a better performance than the TNM staging system ( 6 , 21 , 22 ). In addition, other studies have incorporated genomic data, such as DNA methylation ( 23 ), long non-coding RNA ( 24 ), and autophagy-related gene data ( 25 ), into the nomogram and successfully shown that the developed nomogram has a better discrimination ability than the TNM staging system.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A clinical prognostic model for patients with esophageal squamous cell carcinoma based on circulating tumor DNA mutation features

Liu

Cheng

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundFew predictive models have included circulating tumor DNA (ctDNA) indicators to predict prognosis of esophageal squamous cell carcinoma (ESCC) patients. Here, we aimed to explore whether ctDNA can be used as a predictive biomarker in nomogram models to predict the prognosis of patients with ESCC.MethodsWe included 57 patients who underwent surgery and completed a 5-year follow-up. With next-generation sequencing, a 61-gene panel was used to evaluate plasma cell-free DNA and white blood cell genomic DNA from patients with ESCC. We analyzed the relationship between the mutation features of ctDNA and the prognosis of patients with ESCC, identified candidate risk predictors by Cox analysis, and developed nomogram models to predict the 2- and 5-year disease-free survival (DFS) and overall survival (OS). The area under the curve of the receiver operating characteristic (ROC) curve, concordance index (C-index), calibration plot, and integrated discrimination improvement (IDI) were used to evaluate the performance of the nomogram model. The model was compared with the traditional tumor-nodes-metastasis (TNM) staging system.ResultsThe ROC curve showed that the average mutant allele frequency (MAF) of ctDNA variants and the number of ctDNA variants were potential biomarkers for predicting the prognosis of patients with ESCC. The predictors included in the models were common candidate predictors of ESCC, such as lymph node stage, angiolymphatic invasion, drinking history, and ctDNA characteristics. The calibration curve demonstrated consistency between the observed and predicted results. Moreover, our nomogram models showed clear prognostic superiority over the traditional TNM staging system (based on C-index, 2-year DFS: 0.82 vs. 0.64; 5-year DFS: 0.78 vs. 0.65; 2-year OS: 0.80 vs. 0.66; 5-year OS: 0.77 vs. 0.66; based on IDI, 2-year DFS: 0.33, p <0.001; 5-year DFS: 0.18, p = 0.04; 2-year OS: 0.28, p <0.001; 5-year OS: 0.15, p = 0.04). The comprehensive scores of the nomogram models could be used to stratify patients with ESCC.ConclusionsThe novel nomogram incorporating ctDNA features may help predict the prognosis of patients with resectable ESCC. This model can potentially be used to guide the postoperative management of ESCC patients in the future, such as adjuvant therapy and follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Even early-stage patients who have undergone surgery relapse after a period of time. More than 80% of patients die of metastasis and recurrence, and the overall 5-year survival rate of EC is 15–25% ( 5 , 6 ).…”

Section: Introductionmentioning

confidence: 99%

A clinical prognostic model for patients with esophageal squamous cell carcinoma based on circulating tumor DNA mutation features

Liu

Cheng

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…It allows the three-dimensional distribution of optical probes in the focal area to be reconstructed 2,5 . Tumor, node and metastatic staging systems are commonly used in evaluating tumor development and staging 6,7 . For tumor staging by optical molecular technology, tumor spread can be seen as a multi-source problem.…”

Section: Introductionmentioning

confidence: 99%

Multi-source bioluminescene tomography reconstruction approach base on subspace decision

Xiao¹,

Guo²,

He³

et al. 2023

Medical Imaging 2023: Image Processing

View full text Add to dashboard Cite

Bioluminescence tomography (BLT) reconstruction is an ill-posed problem. A class of strategy based on the permissible region (PR) reduces the ill-posed by reducing the space. However, in multi-objective reconstruction, the strategy is challenging to fit the sources of different positions. In this study, a subspace decision (SD) method is proposed, which transforms the traditional single permissible region into multiple spatially continuous subspaces by clustering, and performs spatial shrinkage optimization for each of them. In addition, a plug-and-play sliding single polyline module is introduced to analyze and cluster the reconstruction results each time to obtain the number and distribution of subspaces contained in the results. SD method does not rely on any specific reconstruction or clustering algorithm, so it has great flexibility. Experiment results show that the SD approach can more accurately obtain the spatial distribution information of different numbers of sources distributed in different locations and ensure the quality of multi-source BLT reconstruction.

show abstract

“…Consequently, NCRT takes an unshakable position in comprehensive anti-tumor therapy. With the addition of adjuvant therapy, pathological TNM stage is seemingly not so reliable in predicting the prognosis of neoadjuvant therapy in contrast with surgery alone [7]. Thus, to help determine prognoses, the imaging and pathological approaches which aim to assess tumor regression were always regarded as important evaluation means [8].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of positive lymph node regression grade to Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma

Zhou

Liu

Guo

et al. 2023

Preprint

View full text Add to dashboard Cite

Background and Purpose To assess the relationship between metastatic lymph node (LN) responder status and recurrence-free survival (RFS) in patients undergoing neoadjuvant chemoradiotherapy (NCRT).Materials and Methods We retrospectively reviewed 304 patients with local advanced esophageal squamous cell carcinoma received NCRT followed by esophagectomy. For 112 patients with positive node, according to the proportion of residual viable tumor cells area within the whole tumor beds of all metastatic LNs, we classified LN-tumor regression grade (LN-TRG) into four categories: grade 1, 0%; 2, < 10%; 3, 10–50%; 4, > 50%. Patients with grade 1 LN-TRG of were considered LN responders, and those with grades 2–4, as LN nonresponders. Univariate and multivariate analyses of recurrence-free survival (RFS) were estimated by a Cox regression model, Kaplan-Meier curve, and log-rank test.Results The median follow-up time of a total of 112 patients was 29.6 months. 52 (46.4%) patients have experienced recurrence. In Cox univariate analysis, LN responder status, nerve invasion, and lymphovascular invasion significantly correlated with RFS. Multivariate analysis for RFS revealed that LN responder status (P < 0.05) was an independent prognostic factor. The 3-year RFS rates for patients with LN-TRG of 1 to 4 grades were 72.7%, 76.5%, 37.4%, and 28.5%, respectively, and the median RFS times were not reach, 43.56 months, 28.09 months, 22.77 months, respectively.Conclusions LN responder status is an independent prognostic factor for RFS in esophageal cancer patients who received NCRT.

show abstract

A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery

Cited by 11 publications

References 80 publications

A clinical prognostic model for patients with esophageal squamous cell carcinoma based on circulating tumor DNA mutation features

A clinical prognostic model for patients with esophageal squamous cell carcinoma based on circulating tumor DNA mutation features

Multi-source bioluminescene tomography reconstruction approach base on subspace decision

Prognostic Significance of positive lymph node regression grade to Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About